Skip to main content

Table 2 The effects of pharmacological treatment of MSCs

From: Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders

Drug Target cells Clinical effect MSC-mediated hematopoiesis MSC-mediated bone regeneration Mechanism(s) in MSCs References
ASA Broad cells Anti-inflammation N/T Telomerase activity↑ [33]
EPO Erythroid progenitors Erythropoiesis EPOR/Stat5 pathway↑ [34]
PTH Osteoblasts/Osteoclasts Osteoporosis CDH11 expression↑ [35]
VK2 Osteoblasts Osteoporosis CXCL12 expression↓ [37]
OICS N/A Osteoporosis CXCL12 and VCAM1 expression↓ [36]
  1. Up arrows indicate up-regulation or activation. Down arrows indicate down-regulation or inactivation
  2. ASA acetylsalicylic acid (aspirin), EPO erythropoietin, EPOR erythropoietin receptor, MSC mesenchymal stromal/stem cell, N/T not tested, OICS osteo-inductive cocktail (dexamethasone, phosphate, and vitamin C ), PTH parathyroid hormone, VCAM1 vascular cell adhesion protein 1, VK2 vitamin K2